Original Article
  

Observation on the Therapeutic Effect and Mechanism of Activated Polyethylene Glycol on Allergic Rhinitis Animal Models

Abstract

Allergic rhinitis (AR), as a chronic disease, seriously affects the quality of life of patients while concurrently exerting a significant economic and healthcare burden on the medical system. However, the existing treatment methods have certain limitations, and more effective treatment strategies are needed. To this end, we proposed an ovalbumin-induced guinea pig model of AR to investigate the potential impact of activated polyethylene glycol (PEG) with varying molecular weights and concentrations in local nasal treatment.
The therapeutic effect was evaluated by behavioral score, serological detection, and histopathological observation.
The behavioral assessment demonstrated significant alleviation of sneezing frequency, nasal pruritus, and clear nasal discharge in the activated PEG-600 treatment groups relative to the sham group. However, statistical analysis revealed no appreciable intergroup differences between the activated PEG-3400 treatment groups and the sham group. Histopathological evaluation disclosed a marked reduction in eosinophilic infiltration in the activated PEG-600 group, accompanied by preservation of nasal mucosal structural integrity and notable attenuation of inflammatory infiltration. In contrast, the activated PEG-3400 group exhibited comparatively limited therapeutic efficacy, demonstrating only a subtle reduction in inflammatory cell counts and more pronounced disorganization of mucosal epithelial architecture compared to the PEG-600-treated group. Serum immunological profiling indicated that while local inflammatory markers showed evidence of mitigation, systemic immune parameters remained unaffected by either activated PEG formulation.
These findings underscore the differential efficacy profile between PEG-600 and PEG-3400 derivatives in ameliorating AR symptoms, among which PEG-600 exhibits superior anti-inflammatory effects.

1. Pawankar R, Canonica GW, Holgate ST, Lockey RF. Allergic rhinitis and its impact on asthma. WAO J. 2011;4(Suppl 3):S3-9.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147-334.
3. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.
4. Akdis CA, Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy. 2000;55(6):522-30.
5. Romagnani S. The role of lymphocytes in allergic disease. J Allergy Clin Immunol. 2000;105(3):399-408.
6. Meltzer EO. The pathophysiology, diagnosis, and treatment of allergic rhinitis: introduction. J Allergy Clin Immunol. 2001;108(1 Suppl):S4-8.
7. Ciprandi G. Nasal inflammation in allergic rhinitis: from pathophysiology to therapy. International J Immunopathol Pharmacol. 2010;23(1 Suppl):1-4.
8. Zhang Y, Zhang L. Increasing prevalence of allergic rhinitis in China. Allergy Asthma Immunol Res. 2019;11(2):156-69.
9. Brozek JL. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-76.
10. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proceed. 2010;31(5):375-80.
11. Bernstein JA, Bernstein JS, Makol R, Ward S. Allergic Rhinitis: A Review. JAMA. 2024;331(10):866-77.
12. Scadding GK. Optimal management of allergic rhinitis. Arch Dis Childhood. 2015;100(6):576-82.
13. Canonica GW. Sublingual immunotherapy: World Allergy Organization position paper. World Allergy Organ J. 2013;6(1):1-52.
14. D'Amore A. PEG-based hydrogels for biomedical applications. J Biomed Materials Res Part A. 2010;93(1):1-12.
15. Baxter H. Coseal Surgical Sealant [product monograph]. 2004.
16. Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. J Pharm Sci. 2016;105(2):460-75.
17. Luo X, Jiang J, Wu H, Li M, Wang B. The influences of finite aperture size in photoacoustic computed tomography. Ultrasonics. 2023;133:107042.
18. Luan ZL, Wang YN, Wang HT. [Research progress of animal model of allergic rhinitis]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016;30(13):1090-4.
19. Saito H, Howie K, Wattie J, Denburg A, Ellis R, Inman MD, et al. Allergen-induced murine upper airway inflammation: local and systemic changes in murine experimental allergic rhinitis. Immunology. 2001;104(2):226-34.
20. Wei H, Xu L, Sun P, Xing H, Zhu Z, Liu J. Activation of STAT6 by intranasal allergens correlated with the development of eosinophilic chronic rhinosinusitis in a mouse model. Int J Immunopathol Pharmacol. 2022;36:3946320221109529.
21. Haitchi HM, Holgate ST. New strategies in the treatment and prevention of allergic diseases. Expert Opin Investig Drugs. 2004;13(2):107-24.
22. Bernstein DI, Schwartz G, Bernstein JA. Allergic Rhinitis: Mechanisms and Treatment. Immunol Allergy Clin North Am. 2016;36(2):261-78.
23. Piao CH, Fan Y, Nguyen TV, Song CH, Kim HT, Chai OH. PM2.5 exposure regulates Th1/Th2/Th17 cytokine production through NF-κB signaling in combined allergic rhinitis and asthma syndrome. Int Immunopharmacol. 2023;119:110254.
Files
IssueArticles in Press QRcode
SectionOriginal Article(s)
Keywords
Guinea pig Inflammation mediators Nasal mucosa Polyethylene glycols
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Wu W, Yang L, Fu B, Lv H, Wu H. Observation on the Therapeutic Effect and Mechanism of Activated Polyethylene Glycol on Allergic Rhinitis Animal Models. Iran J Allergy Asthma Immunol. 2025;:1-9.